REVA Receives CE Mark for Fantom
April 03, 2017 21:00 ET
|
REVA Medical Inc
SAN DIEGO, April 03, 2017 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce it has received CE Mark approval for its Fantom drug-eluting bioresorbable...
REVA to Hold Briefing Call on Q3 2016 Financial Results
November 02, 2016 20:59 ET
|
REVA Medical Inc
SAN DIEGO, Nov. 02, 2016 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) will hold its quarterly briefing call to discuss the Company’s financial results through September...
REVA Releases Positive Data for Fantom at TCT
October 31, 2016 21:13 ET
|
REVA Medical Inc
SAN DIEGO, Oct. 31, 2016 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce that it released final six-month safety data on the complete patient...
REVA to Present at TCT 2016
October 24, 2016 07:00 ET
|
REVA Medical Inc
SAN DIEGO, Oct. 24, 2016 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce the Company’s scheduled presentations during the upcoming Transcatheter...
REVA Completes Submission of CE Mark Application
August 02, 2016 20:01 ET
|
REVA Medical Inc
SAN DIEGO, Aug. 02, 2016 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce that it has submitted an application for CE Marking of its Fantom scaffold,...
REVA Sponsors Symposium at EuroPCR 2016
May 18, 2016 19:00 ET
|
REVA Medical Inc
SAN DIEGO, May 18, 2016 (GLOBE NEWSWIRE) -- Today at the Paris Course on Revascularization (“EuroPCR”), REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) sponsored a symposium entitled,...
REVA Releases Positive Clinical Results for Fantom
May 17, 2016 19:00 ET
|
REVA Medical Inc
SAN DIEGO, May 17, 2016 (GLOBE NEWSWIRE) -- At the Paris Course on Revascularization (“EuroPCR”) being held this week in Paris, France, REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”)...
REVA Achieves Target Patient Enrollment in FANTOM II Trial
February 23, 2016 18:10 ET
|
REVA Medical Inc
SAN DIEGO, Feb. 23, 2016 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce it has achieved the targeted enrollment of 110 patients in Cohort B of...
REVA Announces Clinical Enrollment Progress and Anticipated $11.4 Million Cash Receipt
February 10, 2016 18:20 ET
|
REVA Medical Inc
SAN DIEGO, Feb. 10, 2016 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce that it has enrolled over 200 patients in a clinical study of its Fantom®...
REVA to Present at J.P. Morgan Healthcare Conference
January 07, 2016 19:21 ET
|
REVA Medical Inc
SAN DIEGO, Jan. 07, 2016 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce its Chief Executive Officer, Ms. Reggie Groves, is scheduled to present...